Sales & Marketing News | pharmaphorum

News

Indivior relieves Suboxone hangover with $385m deal

Indivior has reached an agreement to settle all outstanding claims over allegations of improper marketing of its opioid use disorder drug Suboxone Film in the US.

News

EU clears path for Pfizer’s takeover of Seagen

Pfizer’s $43 billion acquisition of antibody-drug conjugate specialist Seagen has been given the go-ahead by the authorities in the EU, clearing a key remaining obstacle t

News

Pfizer sets Paxlovid price at nearly $1,400 per course

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year

News

UCB bags FDA approval for second myasthenia gravis drug

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hope

News

Seagen wins future royalties in Enhertu patent dispute

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in da

News

Keytruda gets surgery-spanning OK from FDA in early NSCLC

MSD’s Keytruda has become the first immunotherapy in the US that can be used continuously, before and after surgery, in patients with early-stage non-small cell lung cance

Indivior relieves Suboxone hangover with $385m deal

EU clears path for Pfizer’s takeover of Seagen

Pfizer sets Paxlovid price at nearly $1,400 per course

UCB bags FDA approval for second myasthenia gravis drug

Seagen wins future royalties in Enhertu patent dispute

Keytruda gets surgery-spanning OK from FDA in early NSCLC

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks